|
[8]
|
Lactobacillus acidophilus and Bifidobacterium bifidum
|
Double-blinded, placebo-controlled, randomized study, T2D females aged 50–65 years
|
Placebo group: n = 10; Probiotic group: n = 10
|
2 daily doses of 100 mL symbiotic shake containing 4 × 108 CFU/100 mL Lactobacillus acidophillus, 4 × 108 CFU/100 mL Bifidobacterium bifidum
|
45 days
|
↓ Glycemia
|
|
[9]
|
Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12
|
Double-blinded, randomized controlled clinical trial, T2D patients aged 30–60 years
|
Placebo group: n = 32; Probiotic group: n = 32
|
300 g/day of probiotic and conventional yogurt day 1: 7,23 × 106 of L. acidophilus La5 and 6.04 × 106 cfu/g of B. lactis Bb12
|
6 weeks
|
↓ Fasting blood glucose and HbA1c
|
|
↑ Erythrocyte SOD and GPx
|
|
↑ Total antioxidant capacity
|
|
[10]
|
L. acidophilus NCFM
|
Double-blinded, placebo-controlled, randomized study, T2D males
|
Placebo group: n = 24; Probiotic group: n = 24
|
-
|
4 weeks
|
Preserved insulin sensitivity
|
|
No effect on systemic inflammatory response
|
|
[117]
|
Lactobacillus rhamnosus GG (ATCC 53 103) and Bifidobacterium lactis Bb12
|
Prospective, randomized study, mother–baby pairs
|
Dietetic Intervention + probiotics: n = 85; Dietetic Intervention + placebo: n = 86; Control + placebo: n = 85
|
Lactobacillus rhamnosus GG: 1010 CFU/day; Bifidobacterium lactis Bb12: 1010 CFU/day
|
33 months
|
↓ Risk of GDM
|
|
[118]
|
Lactobacillus rhamnosus GG, ATCC 53 103 and Bifidobacterium lactis Bb12
|
Randomized, prospective, parallel-group, combined dietary counselling, pregnant women
|
Diet + probiotics: n = 85; Diet + placebo: n = 86; Control + placebo: n = 85
|
Lactobacillus rhamnosus: 1010 CFU/day; Bifidobacterium lactis Bb12: 1010 CFU/day
|
18 months
|
↓ Blood glucose
|
|
↓ Insulin
|
|
↓ Insulin sensitivity
|
|
[119]
|
L. plantarum WCFS1
|
Double-blinded, randomized crossover study, healthy subjects
|
n = 14
|
1012 CFU
|
6 hours
|
↓ Degradation of transepithelial electrical resistance
|
|
↑ ZO-1 in tight junctions
|
